Vaccine improves survival for melanoma patients

Long-term use of a new vaccine is offering hope to advanced melanoma patients with increased survival rates and a greater chance of stopping or reversing the cancer.

About 50 patients in South Australia with inoperable and advanced melanoma have received regular doses of the vaccine -  vaccinia melanoma cell lysate (VMCL) - as part of their treatment plan over the past 10 years.

Results of the University of Adelaide study show that